Table 1 Description of the studies included in the meta-analysis
Source | Year | Patients | Mean Age (years ± SD) | Setting | Time of administration | Mean Baseline LVEF % ± SD | Control | Follow-up | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Levosimendan | Control | Â | Â | Levosimendan | Control | Â | Â |
Al-Shawaf et al. [35] | 2006 | 30 | 60.5 ± 1 1 | 58 ± 10 | Type 2 diabetes with LCOS after CABG. | Post intervention | 29 ± 6 | 31 ± 6 | Milrinone | Hospital stay |
Alvarez et al. [36] | 2005 | 30 | 71.5 ± 5.2 | 71.9 ± 5.2 | Elective CABG with LCOS | Post intervention | 35 ± 5 | 37 ± 4 | Dobutamine | Hospital stay |
Alvarez et al. [37] | 2006 | 50 | 71.2 ± 7.2 | 67.0 ± 8.0 | Elective CABG with LCOS | Post intervention | 35 ± 4 | 34 ± 5 | Dobutamine | Hospital stay |
Barisin et al. [38] | 2004 | 33 | 62.4 ± 7.1 | 57.9 ± 10.4 | Elective OPCAB with good LV function | Pre- intervention | 62 ± 8 | 58 ± 10 | Placebo | Hospital stay |
De Hert et al. [39] | 2007 | 30 | 67 ± 11 | 69 ± 10 | Elective CABG | Intraoperatively | 24 ± 6 | 27 ± 3 | Milrinone | Hospital stay |
De Hert et al. [40] | 2008 | 60 | 67.5 ± 9.5 | 69 ± 10 | Elective CABG | Inraoperatively | 22 ± 5 | 25 ± 3 | Milrinone | Hospital stay |
De Luca et al. [41] | 2005 | 26 | 58.6 ± 8.7 | 57.1 ± 9.3 | Acute MI undergoing PCI | Post intervention | 28 ± 3 | 30 ± 3 | Placebo | Hospital stay |
Eriksson et al. [42] | 2009 | 60 | 64 ± 10 | 64 ± 10 | Elective CABG with LVEF<50% | Intraoperatively | 36 ± 8 | 36 ± 8 | Placebo | Hospital stay |
Fuhrmann et al. [33] | 2008 | 32 | 68 ± 74 | 68 ± 8.1 | Cardiogenic shock after acute MI | Post intervention | 22 ± 9 | 27 ± 10 | Enoximone | Hospital stay |
Husedzinovic et al. [43] | 2005 | 24 | 61 ± 5.4 | 61 ± 5.3 | Elective OPCAB with normal LVEF | Pre- intervention | 56 ± 5 | 59 ± 2 | placebo | Hospital stay |
Jarvela et al. [44] | 2008 | 24 | 69 ± 11 | 67 ± 10 | Elective AVR and CABG | Intraoperatively | 50 ± 4 | 65 ± 5 | Placebo | Hospital stay |
Levin et al. [45] | 2008 | 137 | 62.4 | 61.7 | LCOS after elective CABG | Post intervention | 37 ± 4 | 38 ± 5 | Dobutamine | Hospital stay |
Lilleberg et al. [46] | 1998 | 23 | 56.9 ± 7.9 | 59 ± 5.7 | Elective low risk CABG | Post intervention | 61 ± 9 | 58 ± 9 | Placebo | Hospital stay |
Samimi-Fard et al. [47] | 2008 | 22 | 65 ± 12 | 63 ± 11 | Acute MI with Cardiogenic shock after PCI | Post intervention | 29 ± 2 | 30 ± 3 | Dobutamine | Two years |
Sonntag et al. [48] | 2004 | 24 | 60 | 60 | PCI after acute MI | Post intervention | 58 ± 3 | 62 ± 4 | Placebo | Hospital stay |
Tritapepe et al. [49] | 2006 | 24 | 66.5 ± 5.9 | 69.5 ± 5.6 | Elective CABG | Pre- intervention | 50 ± 7 | 52 ± 5 | Placebo | Hospital stay |
Tritapepe et al. [1] | 2009 | 106 | 66.5 ± 7.8 | 64. ± 8 | Elective CABG | Pre- intervention | 44 ± 10 | 42 ± 11 | Placebo | Hospital stay |